DS
AUPH icon

DRW Securities’s Aurinia Pharmaceuticals AUPH Stock Holding History

DRW Securities’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,000
Closed -$124K – 251
2022
Q1 		$124K Sell
10,000
-25,200
-72% -$389K ﹤0.01% 262
2021
Q4 		$805K Buy
+35,200
New +$834K 0.02% 106

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DRW Securities's AUPH Position: Q3 2025 in Review

DRW Securities sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2025, closing a stake of 27,009 shares — an estimated $229K sold.

DRW Securities first reported a position in AUPH in Q1 2018 and held it in 6 quarters. The position peaked at $482K in Q1 2023. 242 funds tracked by Wall St. Rank hold AUPH as of Q3 2025.

  • DRW Securities reported no remaining Aurinia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • DRW Securities sold 27,009 Aurinia Pharmaceuticals shares in Q3 2025, an estimated $229K.
  • DRW Securities first reported a position in Aurinia Pharmaceuticals in Q1 2018 and held it in 6 quarters.
  • DRW Securities's Aurinia Pharmaceuticals position peaked at $482K in Q1 2023.
  • 242 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2025.

Based on DRW Securities's 13F filing for Q3 2025, filed 14 Nov 2025.